• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Pavmed

DTW Podcast: Geoff Martha updates Medtronic’s new course; AJAX CEO Duke Rohlen is funding innovation differently

February 26, 2021 By Tom Salemi Leave a Comment

Less than a year into his role as CEO, Geoff Martha and the Medtronic leadership has overseen a significant reorganization of medtech’s largest player. In our closing keynote conversation, Martha says the company is clearing a minor COVID-19 bump and sees open road for the company to continue to grab share from competitors. Martha details […]

Filed Under: Business/Financial News, Device Talks Podcasts, Featured, Special Content Tagged With: Abiomed, ajaxhealth, Asensus Surgical, becton dickinson, DeviceTalks Weekly, Medtronic, Pavmed, Scanwell Health, TransEnterix, Verb Surgical, VIDA FLaSH Acquisitions, Zeus

PavMed to spin off subsidiary Lucid Diagnostics

February 22, 2021 By Sean Whooley Leave a Comment

Pavmed (NSDQ:PAVM) announced today that its majority-owned subsidiary Lucid Diagnostics will spin off into a separate public company. In a news release, Pavmed said Lucid Diagnostics intends to spin off if favorable market conditions continue to hold, whether it be through an initial public offering (IPO) or a business combination with a healthcare special purpose acquisition corporation. […]

Filed Under: Business/Financial News, Endoscopic, Featured, Initial Public Offering (IPO), Mergers & Acquisitions, Otolaryngology/Ear, Nose & Throat (ENT), Wall Street Beat Tagged With: Lucid Diagnostics, Pavmed

Pavmed closes $12.4m offering

January 11, 2021 By Sean Whooley

Pavmed (NSDQ:PAVM) announced last week that it closed a registered direct offering of common stock shares worth $12.4 million. New York-based Pavmed’s previously announced offering included 6 million shares of common stock at a price of $2.24 per share, priced at-the-market under Nasdaq rules, according to a news release. The company estimates that the net proceeds […]

Filed Under: Business/Financial News, Diagnostics, Funding Roundup Tagged With: Pavmed

Pavmed raises $7.8M

August 12, 2020 By Sean Whooley

Pavmed (NSDQ:PAVM) filed an SEC Form D to confirm the sale of $7.75 million in an offering of debt and options/warrants to purchase other securities. In selling the $7.75 million, New York-based Pavmed reached its total offering amount in the new notice, which made its first sale on Aug. 5. Pavmed did not intend for the […]

Filed Under: Business/Financial News, Diagnostics, Funding Roundup Tagged With: Pavmed

Pavmed completes $4.1m offering

May 4, 2020 By Sean Whooley

Pavmed (NSDQ:PAVM) filed an SEC Form D to confirm the sale of more than $4 million in debt, options, warrants and other rights to acquire securities. The medical device company completed its total offering of approximately $4.1 million, having made its first sale on April 30, according to the filing. It took just one investor to […]

Filed Under: Business/Financial News, Diagnostics, Funding Roundup Tagged With: FDA, Pavmed

Pavmed to resubmit carpal tunnel device 510(k) application

March 9, 2020 By Nancy Crotti

Pavmed (NSDQ:PAVM) said today that it has reapplied for FDA 510(k) clearance for its CarpX device designed to treat carpal tunnel syndrome. In August 2018, the FDA group reviewing the application for CarpX requested that the company resubmit the application because the group hadn’t reached a consensus within the designated review period. The resubmission incorporates data […]

Filed Under: 510(k), Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: FDA, Pavmed

Pavmed’s Lucid Diagnostics enters clinical trial with U of Penn

March 2, 2020 By Sean Whooley

Pavmed (NSDQ:PAVM) announced today that its majority-owned subsidiary Lucid Diagnostics entered into a clinical trial research agreement with the University of Pennsylvania to observe its EsoCheck esophageal cell collection device. EsoCheck with “collect & protect technology” is designed to offer a less invasive, more efficient and cost-effective alternative to endoscopic biopsies when managing patients with eosinophilic […]

Filed Under: Clinical Trials, Endoscopic, Featured, Otolaryngology/Ear, Nose & Throat (ENT) Tagged With: Lucid Diagnostics, Pavmed, University of Pennsylvania

Pavmed gains FDA breakthrough nod for esophageal pre-cancer test

February 27, 2020 By Nancy Crotti

Pavmed (NSDQ:PAVM) recently announced that its Lucid Diagnostics subsidiary has received FDA breakthrough device designation for its EsoGuard esophageal DNA test. The test uses esophageal samples collected using Lucid’s 510(k)-cleared EsoCheck cell collection device from certain patients at elevated risk for esophageal dysplasia due to chronic gastroesophageal reflux disease (GERD). EsoGuard and EsoCheck are designed to […]

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Oncology Tagged With: FDA, Pavmed

Pavmed back in NASDAQ compliance

January 13, 2020 By Nancy Crotti

Pavmed (NSDQ:PAVM) said today that it has received formal notice from NASDAQ that it has returned to compliance with the stock exchange’s listing rule after 10 consecutive days with a closing bid price of at least $1 per share. NASDAQ warned the company in November that it was in danger of delisting due to poor […]

Filed Under: Business/Financial News, Catheters, Featured, Surgical, Wall Street Beat Tagged With: NASDAQ, Pavmed

Pavmed threatened with stock exchange delisting

November 4, 2019 By Nancy Crotti

Pavmed (NSDQ:PAVM) is in danger of losing its listing on the NASDAQ exchange, according to a report filed with the Securities & Exchange Commission. In August last year, the FDA group reviewing Pavmed’s 510(k) application for its CarpX minimally invasive carpal tunnel release device asked the company to resubmit the application because the group hadn’t reached […]

Filed Under: Business/Financial News, Wall Street Beat Tagged With: FDA, NASDAQ, Pavmed, Securities & Exchange Commission (SEC)

Pavmed touts FIH CarpX study launch in pursuit of FDA 510(k) resubmission

May 21, 2019 By Fink Densford

Pavmed (NSDQ:PAVM) said yesterday that it launched a first-in-human safety study of its CarpX device to support a planned FDA 510(k) resubmission. The CarpX is a percutaneous device designed to allow the operating physician to relieve compression of the median nerve without a surgical incision. The system combines a balloon catheter with bipolar radio-frequency cutting electrodes […]

Filed Under: 510(k), Clinical Trials, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Pavmed

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 5
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS